Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction
JACC: Heart Failure · 2024-06 · 12 (6) · 999-1011
DOI: 10.1016/j.jchf.2024.02.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024-06. Verfasst von Senthil Selvaraj und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Dur…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure (HF)-related symptoms and outcomes in HF with preserved ejection fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF, dapagliflozin altered ketone and fatty acid metabolites vs placebo; however, metabolite signatures of SGLT2is have not been well elucidated in HFpEF. OBJECTIVES: The goal of this study was to assess whether SGLT2i treatment altered systemic metabolic pathways and their relationship to outcomes in HFpEF. METHODS: Targeted profiling of 64 metabolites was performed from 293 participants in PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction Heart Failure), a 12-week, placebo-controlled trial of dapagliflozin. Linear regression assessed changes in metabolite factors defined by principal components analysis (PCA) with dapagliflozin vs placebo. The relationship between changes in metabolite factors with changes in study endpoints was also assessed. RESULTS: The mean age was 70 ± 11 years, 58% were female, and 29% were Black. There were no significant differences in 12 PCA-derived metabolite factors between treatment arms, including metabolites reflecting ketone, fatty acid, or branched-chain amino acid (BCAA) pathways. Combining treatment arms, changes in BCAAs and branched-chain ketoacids were negatively associated with changes in N-terminal pro-B-type natriuretic peptide; changes in medium-/long-chain acylcarnitines were positively associated with changes in N-terminal pro-B-type natriuretic peptide and negatively associated with changes in 6-minute walk test distance; and changes in ketones were negatively associated with changes in weight, without treatment interaction. CONCLUSIONS: Leveraging targeted metabolomics in a placebo-controlled SGLT2i trial of HFpEF, dapagliflozin did not alter systemic metabolic as reflected by circulating metabolites, in contrast with reported effects in HF with reduced ejection fraction. Metabolite biomarkers reflecting BCAA, ketone, and fatty acid metabolism were associated with markers of disease severity, suggesting a role for potential novel treatment targets. (Dapagliflozin in PRESERVED Ejection Fraction Heart Failure [PRESERVED-HF]; NCT03030235).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Durham, North Carolina, USA.
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.
- Duke Molecular Physiology Institute, Durham, North Carolina, USA.
- Duke Molecular Physiology Institute, Durham, North Carolina, USA; Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- NIDDK NIH HHS
- AstraZeneca Pharmaceuticals LP
Zitieren
APA
Selvaraj, S., Patel, S., Sauer, A. J., McGarrah, R. W., Jones, P., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Muehlbauer, M. J., Newgard, C. B., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Shah, S. H., Kosiborod, M. N., & PRESERVED-HF Investigators (2024). Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 12(6), 999-1011. https://doi.org/10.1016/j.jchf.2024.02.018
Vancouver
Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, et al. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2024;12(6):999-1011. doi:10.1016/j.jchf.2024.02.018
BibTeX
@article{Selvaraj2024,
author = {Selvaraj, Senthil and Patel, Shachi and Sauer, Andrew J and McGarrah, Robert W and Jones, Philip and Kwee, Lydia Coulter and Windsor, Sheryl L and Ilkayeva, Olga and Muehlbauer, Michael J and Newgard, Christopher B and Borlaug, Barry A and Kitzman, Dalane W and Shah, Sanjiv J and Shah, Svati H and Kosiborod, Mikhail N and PRESERVED-HF Investigators, PRESERVED-HF Investigators},
title = {Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {6},
pages = {999--1011},
doi = {10.1016/j.jchf.2024.02.018}
}
EUVIMED